CSL has released an ASX statement confirming that it does not expect to be affected by the trade tariffs of 100% to be imposed on pharmaceutical imports to the US, announced at the end of last week.
The pharma giant noted that plasma products - its main export - are exempted from the tariff rules, and plans for manufacturing capability in the US are well advanced.
CSL Seqirus' Fluad influenza vaccine - the main product it sells in the US - is made in the UK, where the tariff rate is currently 10% and expected to reduce to zero.
Meanwhile, Health Minister Mark Butler has reiterated that the PBS is not up for negotiation amid speculation the tariffs may increase pressure on the government to change the scheme.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Apr 26
